Illumina (NASDAQ:ILMN) vs. Opus Genetics (NASDAQ:IRD) Head-To-Head Analysis

Illumina (NASDAQ:ILMN) and Opus Genetics (NASDAQ:IRD) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings and risk.

Earnings & Valuation

This table compares Illumina and Opus Genetics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Illumina	$4.37 billion	3.94	-$1.22 billion	($6.07)	-17.91
Opus Genetics	$10.99 million	6.19	-$57.53 million	($2.10)	-0.54

Opus Genetics has lower revenue, but higher earnings than Illumina. Illumina is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Illumina has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, Opus Genetics has a beta of -0.02, indicating that its share price is 102% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Illumina and Opus Genetics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Illumina	2	9	8	1	2.40
Opus Genetics	0	0	3	0	3.00

Illumina currently has a consensus target price of $125.89, suggesting a potential upside of 15.81%. Opus Genetics has a consensus target price of $7.33, suggesting a potential upside of 543.27%. Given Opus Genetics’ stronger consensus rating and higher probable upside, analysts clearly believe Opus Genetics is more favorable than Illumina.

Profitability

This table compares Illumina and Opus Genetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Illumina	-22.25%	25.54%	8.62%
Opus Genetics	-429.42%	-283.28%	-144.32%

Insider and Institutional Ownership

89.4% of Illumina shares are held by institutional investors. Comparatively, 15.0% of Opus Genetics shares are held by institutional investors. 0.2% of Illumina shares are held by company insiders. Comparatively, 6.6% of Opus Genetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Illumina beats Opus Genetics on 8 of the 15 factors compared between the two stocks.

About Illumina

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

About Opus Genetics

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.